Notably, the combination of OTX015 with crizotinib, one of several ALKi FDA-approved agents for the treatment of ALK+ non-small cell lung cancer, or with CEP28122, a selective ALKi [29], were found to be highly effective in our ALK+ ALCL cell lines. This evidence concerns the gene ALK and anaplastic large cell lymphoma.